Cabaletta Bio, Inc.

NasdaqGS:CABA Stock Report

Market Cap: US$533.2m

Cabaletta Bio Management

Management criteria checks 4/4

Cabaletta Bio's CEO is Steven Nichtberger, appointed in Jan 2017, has a tenure of 9.33 years. total yearly compensation is $2.40M, comprised of 27.5% salary and 72.5% bonuses, including company stock and options. directly owns 0.86% of the company’s shares, worth $4.56M. The average tenure of the management team and the board of directors is 4.5 years and 6.3 years respectively.

Key information

Steven Nichtberger

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage27.46%
CEO tenure9.3yrs
CEO ownership0.9%
Management average tenure4.5yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

Analysis Article • Mar 24

Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 27

Cabaletta Bio: Do You Buy With The Insiders?

Summary Cabaletta Bio continues to advance its engineered cell therapy pipeline targeting autoimmune diseases, maintaining cautious optimism. Recent insider share purchases have apparently bolstered confidence in CABA’s prospects following key data releases since October. At Q3 2025, CABA reported $60.2 million in cash and $99.7 million in short-term investments, supporting ongoing development. Strengths include promising pipeline updates, while risks remain around cash runway and clinical progress. Read the full article on Seeking Alpha
Seeking Alpha • Jan 06

Cabaletta Bio: Finding Optimism In Dire Straits

Summary Cabaletta Bio, Inc.'s CD19-directed CAR T-cell therapy shows early promise in treating autoimmune diseases, despite limited patient numbers and follow-up time. Financially, Cabaletta Bio has enough cash to operate for 5–6 quarters, assuming no further expense growth or additional financing. Risks include the aggressive nature of CAR T-cell therapy for non-life-threatening diseases and competition from other cell therapy approaches. With a market cap under $150 million, CABA's stock is a potential bargain if they achieve even partial success in their pipeline. Read the full article on Seeking Alpha
Analysis Article • Dec 10

Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 22

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Summary I am buying Cabaletta Bio shares as a speculative play on upcoming clinical trial updates for innovative CAR-T therapies. Despite high volatility in 2024 and the potential for total investment loss, the company’s strong cash position and lack of recent selling point to a bullish outlook. Super-positive testing results announced in mid-November would trigger significant stock gains, with the possibility of oversized returns on investment similar to 2022-23. I rate Cabaletta a Buy for a 12-month outlook, assuming a position size of less than 1% of net portfolio assets, to adequately offset greater-than-normal risk. Read the full article on Seeking Alpha
Analysis Article • Sep 04

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jun 28

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Summary Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. It's stock price rose >$25 due to positive data produced by a drug with the same MoA as CABA-201, showing remarkable results with many patients experiencing full recoveries. Cabaletta stock has been sinking in 2024 however due to slow progress, manufacturing concerns, and disappointing recent data release. Cabaletta plans to continue studies on CABA-201 for various autoimmune conditions, with the next data update due before the end of the year. The next data readout feels crucial - signs of efficacy will be greeted with a surge in share price value, but poor results could drive it back into delisting territory. There is all to play for. Read the full article on Seeking Alpha
Analysis Article • May 22

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 31

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Summary Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with myositis, is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with generalized myasthenia gravis, is expected in the 2nd half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic sclerosis, is expected in the 2nd half of 2024. Read the full article on Seeking Alpha
Analysis Article • Dec 28

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. By way of example, Cabaletta Bio...
Analysis Article • Sep 12

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Cabaletta Bio...
Analysis Article • Jun 04

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example...
Analysis Article • Feb 11

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Cabaletta Bio...
Analysis Article • Oct 20

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jul 07

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

CEO Compensation Analysis

How has Steven Nichtberger's remuneration changed compared to Cabaletta Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$175m

Dec 31 2025US$2mUS$660k

-US$168m

Sep 30 2025n/an/a

-US$159m

Jun 30 2025n/an/a

-US$144m

Mar 31 2025n/an/a

-US$127m

Dec 31 2024US$8mUS$646k

-US$116m

Sep 30 2024n/an/a

-US$104m

Jun 30 2024n/an/a

-US$90m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$5mUS$597k

-US$68m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$57m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$2mUS$569k

-US$53m

Sep 30 2022n/an/a

-US$51m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021US$4mUS$542k

-US$46m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$4mUS$516k

-US$33m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$1mUS$437k

-US$22m

Compensation vs Market: Steven's total compensation ($USD2.40M) is about average for companies of similar size in the US market ($USD2.72M).

Compensation vs Earnings: Steven's compensation has been consistent with company performance over the past year.

CEO

Steven Nichtberger (64 yo)

9.3yrs
Tenure
US$2,401,555
Compensation

Dr. Steven A. Nichtberger, M.D., serves as managing partner of GBF Advisors, LLC. Dr. Nichtberger is an adjunct professor at The Wharton School at the University of Pennsylvania. He is Co-Founder of Cabale...

Leadership Team

NamePositionTenureCompensationOwnership
Steven Nichtberger
Co-Founder9.3yrsUS$2.40m0.86%
$ 4.6m
David Chang
Chief Medical Officer6.9yrsUS$1.24m0.0054%
$ 28.8k
Gwendolyn Binder
President of Science & Technologyno dataUS$1.26m0.019%
$ 102.4k
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno datano datano data
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno datano datano data
Anup Marda
Chief Financial Officer7.3yrsUS$1.53mno data
Qing Yuan
Chief Technology Officer1.9yrsno datano data
Samik Basu
Chief Scientific Officer4.5yrsno datano data
Michael Gerard
General Counsel & Secretary4.7yrsno datano data
Heather Harte-Hall
Chief Compliance Officer4.5yrsno datano data
Nicolette Sherman
Chief Human Resources Officer1.5yrsno datano data
Arun Das
Chief Business Officer4.3yrsno datano data
4.5yrs
Average Tenure
52yo
Average Age

Experienced Management: CABA's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Steven Nichtberger
Co-Founder9.3yrsUS$2.40m0.86%
$ 4.6m
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno datano datano data
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno datano datano data
Richard Henriques
Independent Director7.3yrsUS$152.17k0%
$ 0
Carl June
Member of Scientific Advisory Board5.8yrsno datano data
Mark Simon
Independent Director7.6yrsUS$140.91k0.095%
$ 504.3k
Scott Brun
Independent Director4.9yrsUS$136.84k0%
$ 0
Iain McInnes
Member of Scientific Advisory Board6.3yrsno datano data
Jay Siegel
Member of Scientific Advisory Boardno datano datano data
Georg Schett
Member of Scientific Advisory Board4.3yrsno datano data
Shawn Tomasello
Independent Director2.8yrsUS$119.17k0.014%
$ 74.3k
Catherine Bollard
Independent Director7.1yrsUS$145.57k0.0033%
$ 17.6k
6.3yrs
Average Tenure
64yo
Average Age

Experienced Board: CABA's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 07:02
End of Day Share Price 2026/05/20 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cabaletta Bio, Inc. is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerCantor Fitzgerald & Co.
Samantha Lynn SemenkowCitigroup Inc
Joshua SchimmerEvercore ISI